Edition:
United Kingdom

BB Biotech AG (BION.S)

BION.S on Swiss Exchange

69.55CHF
15 Feb 2019
Change (% chg)

CHF0.20 (+0.29%)
Prev Close
CHF69.35
Open
CHF68.90
Day's High
CHF69.55
Day's Low
CHF68.45
Volume
50,811
Avg. Vol
115,171
52-wk High
CHF74.60
52-wk Low
CHF55.05

Chart for

About

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s... (more)

Overall

Beta: 1.16
Market Cap(Mil.): CHF3,731.19
Shares Outstanding(Mil.): 55.40
Dividend: 2.75
Yield (%): 4.08

Financials

  BION.S Industry Sector
P/E (TTM): 4.38 8.17 19.22
EPS (TTM): 15.37 -- --
ROI: 28.44 14.04 0.45
ROE: 28.44 17.14 15.43

BRIEF-BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

* FY NET LOSS OF CHF 471 MN COMPARED TO A NET GAIN OF CHF 688 MN FOR FULL YEAR OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Feb 2019

BRIEF-BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

* BB BIOTECH INVESTS GAINS OF M&A TRANSACTIONS IN NEW TECHNOLOGIES - DIVIDEND OF CHF 3.05 PROPOSED

18 Jan 2019

BRIEF-BB Biotech Enlarges Its Board Of Directors

* WILL PROPOSE DR. THOMAS VON PLANTA FOR ELECTION TO ITS BOARD OF DIRECTORS.

19 Oct 2018

BRIEF-BB Biotech Q3 Net Gain Up At CHF 242 Mln

* DGAP-NEWS: BB BIOTECH AG: INVESTORS SHOWED RENEWED INTEREST IN BIOTECH STOCKS DURING THE THIRD QUARTER

19 Oct 2018

BRIEF-BB Biotech Q3 Profit Down At CHF 242 Mln

* FOR NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2018 A PROFIT OF CHF 172 MILLION VERSUS CHF 843 MILLION YEAR AGO

11 Oct 2018

Earnings vs. Estimates